Money · Lobbying reports · 119th Congress
H.R. 1672
23 saved lobbying reports name H.R. 1672.
23 reports
Confirmed from the official recordSenate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Lobbying Disclosure Act reports, LDA.gov. This copy was read October 7, 2026 at 9:09 PM Eastern.
Reports that name this bill
The amount is what the report gives for the whole quarter: everything the registrant did for that client, all issues together. A linked name opens that organization’s page on this site.
| Registrant | Client | Amount for the whole quarter | Quarter | Report |
|---|---|---|---|---|
| LMH STRATEGIC SOLUTIONS | ALNYLAM PHARMACEUTICALS, INC. | $50,000.00reported as income | April to June 2026 | Open the report |
| LMH STRATEGIC SOLUTIONS | IONIS PHARMACEUTICALS, INC. | $30,000.00reported as income | April to June 2026 | Open the report |
| HEALTHCARE INSTITUTE OF NEW JERSEY | HEALTHCARE INSTITUTE OF NEW JERSEY | $47,670.00reported as expenses | April to June 2026 | Open the report |
| TROUTMAN STRATEGIES | THE MENDED HEARTS, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS | NOVARTIS | $50,000.00reported as income | April to June 2026 | Open the report |
| TODD STRATEGY GROUP | NOVARTIS, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| IONIS PHARMACEUTICALS, INC. | IONIS PHARMACEUTICALS, INC. | $150,000.00reported as expenses | April to June 2026 | Open the report |
| TIBER CREEK GROUP | TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) | $60,000.00reported as income | April to June 2026 | Open the report |
| TIBER CREEK GROUP | ALNYLAM PHARMACEUTICALS, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| BGR GOVERNMENT AFFAIRS | NOVARTIS | $60,000.00reported as income | April to June 2026 | Open the report |
| HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $180,000.00reported as expenses | April to June 2026 | Open the report |
| NOVARTIS | NOVARTIS | $1,410,000.00reported as expenses | April to June 2026 | Open the report |
| AVENUE SOLUTIONS | GENENTECH USA, INC. | $50,000.00reported as income | April to June 2026 | Open the report |
| THE ALS ASSOCIATION | THE ALS ASSOCIATION | $30,000.00reported as expenses | April to June 2026 | Open the report |
| AMGEN, INC. | AMGEN INC | $2,440,000.00reported as expenses | April to June 2026 | Open the report |
| FORBES-TATE | NOVARTIS, INC. | $50,000.00reported as income | April to June 2026 | Open the report |
| BROWNSTEIN HYATT FARBER SCHRECK, LLP | NOVARTIS | $90,000.00reported as income | April to June 2026 | Open the report |
| VENABLE LLP | ASSOCIATION OF BLACK CARDIOLOGISTS | $30,000.00reported as income | April to June 2026 | Open the report |
| DLA PIPER LLP (US) | NOVARTIS | $60,000.00reported as income | April to June 2026 | Open the report |
| TODD STRATEGY GROUP | ALNYLAM PHARMACEUTICALS, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| SPLITOAK STRATEGIES LLC | ALNYLAM PHARMACEUTICALS, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| FORBES-TATE | IONIS PHARMACEUTICAL, INC. | $30,000.00reported as income | April to June 2026 | Open the report |
| ALNYLAM PHARMACEUTICALS, INC. | ALNYLAM PHARMACEUTICALS, INC. | $450,000.00reported as expenses | April to June 2026 | Open the report |